These price targets are a consensus analysis of 20 brokers.
A number of other institutional investors have also recently modified their holdings of the stock. They presently have a $98.00 price objective on the pharmaceutical company's stock. Leerink Swann reissued an "outperform" rating and issued a $113.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, August 15th. Finally, RBC Capital Markets reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 12th. Citigroup Inc. initiated coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 13th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday, September 27th. Vertex Pharmaceuticals Incorporated's target price was set to 101.8 with an IPO date at 7/24/1991.
Jefferies believe that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) presents a lucrative buying opportunity at the current level, and investors looking to get in the industry should purchase the stock. Also, Director Joshua S. Boger sold 6,500 shares of the company's stock in a transaction dated Wednesday, November 2nd.
The Relative Volume of the company is 0.89 and Average Volume (3 months) is 2 million. The firm has a SMA 50 (Simple Moving Average) of -7.06% and a SMA 200-(Simple Moving Average) of -11.33%. Vertex Pharmaceuticals Incorporated Biotechnology holds an EPS of -0.9 that demonstrates an EPS growth this year at 26.50%.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Tuesday, October 25th. The reported earnings missed the analyst's consensus by $-0.02 with the surprise factor around -11.10%. The gross margin parades a value of 87.40% with the company running a operating margin of -5.00% and a profit margin of -13.20%. The business had revenue of $413.78 million for the quarter, compared to analysts' expectations of $423.53 million. During the same quarter in the previous year, the firm posted ($0.13) EPS.
In Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest quarter ended on 30 Sep 2016, company revealed earnings of $0.16 a share. If you are viewing this news story on another site, it was stolen and reposted in violation of United States and worldwide copyright and trademark legislation. Eqis Capital Management Inc. increased its stake in Vertex Pharmaceuticals by 19.6% in the second quarter. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -10.5% where SMA50 and SMA200 are -7.61% and -12.26% respectively. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The shares were sold at an average price of $86.46, for a total transaction of $104,443.68. The disclosure for this sale can be found here. The company has an Average Rating of 2.25 based on Thomson Reuters I/B/E/S scale of 1-5. 0 analysts assign "Sell" rating for the stock. DNB Asset Management AS boosted its position in Vertex Pharmaceuticals by 8.2% in the second quarter. Sales growth in the quarter for Vertex Pharmaceuticals Incorporated Biotechnology NASDAQ shows a value of 33.60% with Outstanding shares of 255.66. Exxonmobil Investment Management Inc. Eaton Vance Management boosted its stake in Vertex Pharmaceuticals by 142.8% in the second quarter. Following the completion of the sale, the director now owns 274,725 shares of the company's stock, valued at $22,934,043. Mycio Wealth Partners LLC boosted its position in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Wedbush Securities Inc. bought a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $671,000.
Rhumbline Advisers boosted its stake in shares of Vertex Pharmaceuticals Inc. Creative Planning now owns 5,249 shares of the pharmaceutical company's stock valued at $451,000 after buying an additional 102 shares during the period.
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases.